TWST · Twist Bioscience Corporation — research history

Stage produced output that could not be parsed as a valid JSON object. ~6h cooldown before retry.

{"symbol":"TWST","company":"Twist Bioscience Corporation","investigation_summary":"The investigation triggered by 30 Form 4 filings in 14 days is almost entirely routine tax-withholding sales (RSU vesting 'sell to cover') and pre-scheduled 10b5-1 option exercises — not open-market discretionary buying. The CEO's May 28, 2026 filing explicitly shows a Rule 10b5-1 plan adopted in May 2025 with exerc

The Form 4 cluster trigger (8 filings / 5 trades in 14 days) proved to be entirely RSU vesting sell-to-cover transactions — not discretionary open-market buys. CEO Leproust's sole activity was exercising pre-existing options under a May 2025 Rule 10b5-1 plan and selling at $65–69. No insider has made an open-market PURCHASE in the trailing period. Simultaneously, Cathie Wood / ARK Invest has been systematically trimming TWST across multiple weeks in June (reported $279M in weekly liquidations). The stock is up ~139% YTD from $32 to $76, near its 52-week high of $80.50 set June 4. With negative FCF (-$58M TTM), no path to profitability visible in the forward model, and elevated IV (62–81%), there is no mispricing edge, no real insider signal, and no income thesis at this level.

Twist Bioscience is a silicon-chip-based synthetic DNA manufacturer with $376M FY2025 revenue (19% growth), 52%+ gross margins, and consistent quarterly sequential growth. The Form 4 cluster of 9 filings in 14 days resolves almost entirely to sell-to-cover tax withholding on RSU vesting events (S codes, not P purchases) plus pre-established 10b5-1 plans — there are zero open-market discretionary insider buy transactions during this period. CEO Leproust exercised deep ITM options ($8.82 strike) and sold ~$3.2M of shares, all under a prior 10b5-1 plan adopted May 2025. The stock is at an all-time high (+147% YTD), deeply unprofitable (forward P/E N/A, EV/EBITDA -38x), yet commands 35-40x forward revenue — leaving virtually no margin of safety for the long thesis. A path to adjusted EBITDA breakeven in Q4 FY2026 is a real catalyst if achieved but is ~5 months away and uncertain given recent EPS miss (-12.58% surprise last quarter). The DNA synthesis market TAM ($30B by 2035) and new product launches (Complex Genes, LenioBio partnership) support the long-term story but are already largely priced in at current levels.

Investigation triggered by Form 4 cluster (2 real trades in 14 days) reveals both recent transactions are routine sell-to-cover events for RSU tax withholding — CEO Emily Leproust and CFO Robert Werner selling at market, not discretionary purchases. The stock is up 132% YTD on strong Q2 FY26 earnings (beat revenue estimates, raised full-year guidance to ~$460M), gross margins above 50%, and new product launches (Complex Genes, Invenra bispecific licensing). However, with forward P/E of -28.7, at/near 52-week high, no CEO/CFO open-market purchases present, and no identifiable mispricing vs. intrinsic value for a pre-profitability synthetic biology company, there is no anomaly to trade against. The pipeline halts.

The dossier shows zero insider buying, persistent negative earnings/cash flow, and active dilution, while the stock has already surged 90% YTD leaving it fully valued with no margin of safety. Active anti-signals for dilution and pump behavior, combined with no clear asymmetric catalyst or technical support, firmly preclude a trade.

The Form 4 cluster trigger (7 filings / 5 real trades in last 14 days) turned out to be entirely routine: all five transactions on May 4, 2026 were sell-to-cover of RSU tax withholdings by mid-tier executives (Dennis Cho, Patrick Finn, Paula Green, Robert Werner). A sixth filing from director Jan Johannessen was an option-exercise-plus-same-day-sale at $56 — vesting exercise, not a discretionary open-market buy. Cathie Wood's ARK has been trimming TWST across multiple sessions in May 2026 while the stock ran +90% YTD to near 52-week highs of $66. The recent Q2 FY2026 earnings (May 4) did show a revenue beat and raised full-year guidance, with EBITDA breakeven targeted for Q4 FY2026 — but at -24x forward P/E on negative FCF and a stock that has already doubled year-to-date, the risk/reward does not support an asymmetric long. The elevated IV (74-95% ATM) makes this a plausible covered-call or strangle candidate rather than a directional setup.

Twist Bioscience is a synthetic DNA manufacturer using proprietary silicon-chip technology, also operating in NGS tools and antibody discovery services. Revenue grew ~19% YoY to $409M TTM; still deeply unprofitable ($77.7M net loss FY2025). The investigation trigger was a Form 4 cluster of 7 filings in 14 days, but on thorough review ALL transactions are sell-to-cover (code S) for RSU tax withholding obligations — not open-market purchases. There is zero discretionary insider buying anywhere in the recent filing history. The May 4 Q2 FY2026 earnings report was a revenue beat with raised full-year guidance and an announced launch of Complex Genes; however, TWST trades near its 52-week high with no meaningful valuation discount, negative forward P/E, and the stock has already run ~110% in the past year. No edge-in-data anomaly was found.